Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152667 | 0.86 | MET (0.57) | METMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3112440 | 0.85 | MEN1 (0.50) | METMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3119810 | 0.85 | MEN1 (0.50) | METMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3119589 | 0.83 | MEN1 (0.50) | METMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2152510 | 0.81 | HRH3 (0.48) | METMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2152783 | 0.81 | MAPT (0.49) | METMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3103580 | 0.81 | MEN1 (0.48) | METMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL13247308 | 0.80 | MET (0.69) | MET | |
| SCHEMBL3122723 | 0.79 | MET (0.48) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL3114894 | 0.79 | HDAC1 (0.43) | METMEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, RET | MET 1/4885MEN1 121/4885KMT2A 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.